Breaking News

GSK Enters Flu-Vax JV in China

GlaxoSmithKline and Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. have entered into a definitive agreement to form a joint venture focused on developing and manufacturing flu vaccines for the Chinese market.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. have entered into a definitive agreement to form a joint venture focused on developing and manufacturing flu vaccines for the Chinese market. Jean Stéphenne, president and general manager of GlaxoSmithKline Biologicals, said, “This new alliance enables GSK to build new vaccines capability in a critical emerging market such as China. The new joint venture will combine the potential of GSK’s adjuvant technology and expertise...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters